<DOC>
	<DOCNO>NCT00604682</DOCNO>
	<brief_summary>Open label study patient severe plaque type psoriasis . This study look evaluate pharmacodynamic effect CC10004 take 29 day reduce epidermal thickness subject severe placque type psoriasis .</brief_summary>
	<brief_title>Open-Label , Single-Arm Pilot Study Evaluate Pharmacodynamics , Pharmacokinetics , Safety , Preliminary Efficacy CC1004 Subjects With Severe Plaque Type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<criteria>Inclusion Criteria Must understand voluntarily sign informed consent form Must age &gt; = 18 year 65 year time sing informed consent form . Must able adhere study visit schedule protocol requirement Must history severe plaque type psoriasis least 6 month , least 15 % affected total body surface area ( BSA ) Must meet follow clinical laboratory criterion : White Blood Cell Count &gt; = 3000/cu mm &lt; 20,000/cu mm Platelet count &gt; = 100,000/microliters Serum creatinine &lt; = 1.5 mg/dl Total bilirubin &lt; = 2.0 mg/dl AST ( SGOT ) ALT ( SGPT ) &lt; = 1.5 X ULN Must psoriatic plaque &gt; = 2.5 cm diameter ( biopsy ) Must candidate photo/systemic therapy ( subject consider candidate photo/systemic therapy clinician judge subject require systemic therapy ( e.g. , ultraviolet light B ( UVB ) , Psoralens longwave ultraviolet radiation ( PUVA ) , cyclosporine , corticosteroid , methotrexate , oral retinoids , mycophenolate mofetil , thioguanine , hydroxyurea , sirolimus , tacrolimus , azathioprine ) control psoriasis whether subject history receive systemic therapy ) Women child bear potential ( WCBP ) must negative urine pregnancy test Screening ( Visit 1 ) . In addition , sexually active WCBP must agree use two form adequate form contraception throughout trial . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form Pregnant lactating female Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study Current erythrodermic , guttate , pustular psoriasis Use medication metabolize CYP3A4 CYP2A6 pathway within 14 day study medication initiation and/or require use medication study treatment . Drinking ingest grapefruit , grapefruit juice grapefruit containing product within 14 day study medication initiation Use topical therapy ( topical steroid , topical vitamin A D analog preparation , tacrolimus , pimecrolimus , anthralin ) within 14 day study medication initiation ( Exception : Nonmedicated emollient tar shampoo allow ) Use systemic therapy psoriasis Use phototherapy within 28 day study medication initiation Use Humira Remicade within 3 month study medication initiation Use Enbrel within 56 day study medication initiation Use Raptiva within 56 day study medication initiation Use Amevive within 6 month study medication initiation Use investigational drug within 30 day study medication initiation 5 half life know History clinically significant cardiac , endocrinologic , pulmonary , neurologic , psychiatric , hepatic , renal , hematologic , immunologic insufficiency disease major disease Clinically significant abnormality 12lead ECG screen Positive HIV , Hepatitis B Hepatitis C laboratory result screen History active tuberculosis within previous 3 year Clinically significant abnormality chest xray screen CXR take within 6 month screen History positive purify protein derivative ( PPD ) test screen History malignancy within previous five year Evidence skin condition time screen visit psoriasis would interfere evaluation effect study medication psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>psoriasis</keyword>
</DOC>